Ewings Sarcoma Pipeline Analysis Size, Share, Opportunities, And Trends, Forecasts From 2019 To 2024
- Published : Mar 2020
- Report Code : KSI061614761
- Pages : 105
Offered with this report
Market Data and Estimates in Excel
2 Months of Post Sale Analyst Support
Requirement Specific Customization
Ewing’s sarcoma Pipeline Analysis report covers more than 10 drugs currently in different phases of development. Ewing’s sarcoma is a type of cancer which is rare and occurs in the bone and in the soft tissues around the bones. The cancer is common among the teenagers and young adults. Symptoms include pain, swelling and tenderness in the affected regions, fever with no known cause, broken bone with no known cause and unexplained tiredness.
The report provides Ewing’s sarcoma treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are Gradalis, Eisai Co., Ltd., CELLECTAR BIOSCIENCES, INC. and Oncternal Therapeutics among others..
Scope:
By Company
By Phase
By Molecule Type
By Region
By Route of Administration
1. Introduction
1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region
2. Disease Overview
2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology
3. Executive Summary
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities
5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profiling
• Drug Name
• Generic Name
• Synonyms
• Company
• Collaborator
• Route of administration
• Target
• Mechanism of Action
• Technology
• Molecule type
• CAS Number
• Weight
• Chemical Formula
• IUPAC name
• ATC code
5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region
6. Company profiling
6.1. Incyte Corporation
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. SWOT
6.1.5. Recent Development
6.2. Oncternal Therapeutics, Inc
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. SWOT
6.2.5. Recent Development
6.3. Eisai Co., Ltd.
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. SWOT
6.3.5. Recent Development
6.4. SillaJen Inc
6.4.1. Introduction
6.4.2. Financials
6.4.3. Products and Services
6.4.4. SWOT
6.4.5. Recent Development
6.5. MacroGenics, Inc.
6.5.1. Introduction
6.5.2. Financials
6.5.3. Products and Services
6.5.4. SWOT
6.5.5. Recent Development
6.6. Celgene Corporation
6.6.1. Introduction
6.6.2. Financials
6.6.3. Products and Services
6.6.4. SWOT
6.6.5. Recent Development
6.7. NantPharma
6.7.1. Introduction
6.7.2. Financials
6.7.3. Products and Services
6.7.4. SWOT
6.7.5. Recent Development
6.8. Tyme Inc
6.8.1. Introduction
6.8.2. Financials
6.8.3. Products and Services
6.8.4. SWOT
6.8.5. Recent Development
6.9. TESARO, Inc (A GSK Company)
6.9.1. Introduction
6.9.2. Financials
6.9.3. Products and Services
6.9.4. SWOT
6.9.5. Recent Development
6.10. Cellectar Biosciences, Inc.
6.10.1. Introduction
6.10.2. Financials
6.10.3. Products and Services
6.10.4. SWOT
6.10.5. Recent Development
6.11. NanoValent Pharmaceuticals
6.11.1. Introduction
6.11.2. Financials
6.11.3. Products and Services
6.11.4. SWOT
6.11.5. Recent Development
6.12. PharmaMar SA
6.12.1. Introduction
6.12.2. Financials
6.12.3. Products and Services
6.12.4. SWOT
6.12.5. Recent Development
6.13. Salarius Pharmaceuticals
6.13.1. Introduction
6.13.2. Financials
6.13.3. Products and Services
6.13.4. SWOT
6.13.5. Recent Development
6.14. Gradalis
6.14.1. Introduction
6.14.2. Financials
6.14.3. Products and Services
6.14.4. SWOT
6.14.5. Recent Development
6.15. Atlanthera
6.15.1. Introduction
6.15.2. Financials
6.15.3. Products and Services
6.15.4. SWOT
6.15.5. Recent Development
List of Tables
List of Figures
Incyte Corporation
Oncternal Therapeutics, Inc
Eisai Co., Ltd.
SillaJen Inc
MacroGenics, Inc.
Celgene Corporation
NantPharma
Tyme Inc
TESARO, Inc (A GSK Company)
Cellectar Biosciences, Inc.
NanoValent Pharmaceuticals
PharmaMar SA
Salarius Pharmaceuticals
Gradalis
Atlanthera
Related Reports
| Report Name | Published Month | Get Sample PDF |
|---|---|---|
| Connected Agriculture Market Size & Share: Report, 2021-2026 | Sep 2021 | |
| Pyrometer Market Size, Share & Trends: Industry Report, 2021-2026 | Jun 2021 | |
| Radiotherapy Market Size & Share: Industry Report, 2021-2026 | Jul 2021 | |
| Data Center Colocation Market Size & Share: Report, 2023 - 2028 | Jun 2023 | |
| Industrial Enzymes Market: Size, Share, and Insights, 2029 | Mar 2024 |